Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial

Hemodialysis International

Volumn 14, Issue 2, 2010, Pages 168-173

  Keown, Paul A ^a   Churchill, David N ^b   Poulin Costello, Melanie ^b   Lei, Lei ^c   Gantotti, Sandeep ^b   Agodoa, Irene ^c   Gitlin, Matthew ^c   Gandra, Shravanthi R ^c   Mayne, Tracy J ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Amgen Canada Inc   (Canada)

^c AMGEN INC   (United States)

Author keywords

Anemia; Chronic kidney disease; Dialysis; Epoetin alfa; Erythropoiesis stimulating agents; Health related quality of life

Indexed keywords

HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ADULT; AGED; ANALYSIS OF VARIANCE; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POST HOC ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; WEAKNESS; CANADA; CHRONIC KIDNEY FAILURE; HEALTH STATUS; METHODOLOGY; MIDDLE AGED; RENAL REPLACEMENT THERAPY; STANDARD; STATISTICAL ANALYSIS; STATISTICS;

ADULT; AGED; ANEMIA; CANADA; DATA INTERPRETATION, STATISTICAL; EPOETIN ALFA; FATIGUE; FEMALE; HEALTH STATUS; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLACEBOS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS;

EID: 77956405840     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00422.x     Document Type: Article

References (14)

1. McClellan W, Aronoff SL, Bolton WK. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004, 20:1501-1510.
2. Evans RW, Manninen DL, Garrison LP. The quality of life of patients with end-stage renal disease. N Engl J Med 1985, 312:553-559.
3. Spiegel DM, Evans RW, Gitlin M, Mayne TJ. Psychometric evaluation of the National Kidney Dialysis and Kidney Transplantation Study symptom checklist: Reliability and validity. Nephrol Dial Transplant 2009, 24:619-625.
4. U.S. Renal Data System., USRDS. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2008
5. Ibrahim HN, Ishani A, Foley RN, Guo H, Liu J, Collins AJ. Temporal trends in red blood transfusion among US dialysis patients, 1992-2005. Am J Kidney Dis 2008, 52:1115-1121.
6. EPOGEN(R) (Epoetin alfa) Perscribing Information 2007, Amgen Inc., Thousand Oaks, CA, Amgen Inc
7. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990, 300:573-578.
8. Laupacis A, Muirhead N, Keown P, Wong C. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Nephron 1992, 60:302-306.
9. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: Development and final revision of a health status measure. Med Care 1981, 19:787-805.
10. Naughton J, Sevelius G, Balke B. Physiological responses of normal and pathological subjects to a modified work capacity test. J Sports Med Phys Fitness 1963, 44:201-207.
11. Foley RN, Parfrey PS, Morgan J. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000, 58:1325-1335.
12. Muirhead N, Churchill DN, Goldstein M. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol 1992, 12:303-310.
13. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet 2007, 370:415-426.
14. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg 2009, 108:759-769.